查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
瘙癢治療市場：按藥物類型、疾病類型、分銷渠道：2021-2031 年全球機會分析和行業預測
市場調查報告書
商品編碼
1140389

瘙癢治療市場：按藥物類型、疾病類型、分銷渠道：2021-2031 年全球機會分析和行業預測

Pruritus Therapeutics Market By Drug type, By Disease Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 385 Pages | 商品交期: 2-3個工作天內

價格

全球瘙癢治療市場預計在 2021 年達到 78.494 億美元，在 2031 年達到 111.8615 億美元，從 2022 年到 2031 年的複合年增長率為 3.6%。

止癢藥是用於治療瘙癢的藥物。由於皮膚乾燥、過敏和其他疾病等許多問題，皮膚瘙癢會導致皮膚發癢。對各種刺激物（包括灰塵、環境污染物、動物和某些食物）的炎症反應增加，可導致稱為特應性皮炎的濕疹。特應性皮炎通常表現為面部、手臂和腿部出現皮疹、鱗屑和瘙癢等症狀。當人們接觸到可能傷害皮膚的物質（例如化學品）時，就會發生過敏性接觸性皮炎。引起接觸性皮炎的典型產品包括手錶、肥皂、衣服和用刺激性物質製成的珠寶。

多年來，醫療專業人員一直使用外用皮質類固醇治療瘙癢。皮質類固醇是瘙癢和相關瘙癢如 AD、過敏性接觸性皮炎和扁平苔蘚的一線藥物治療。瘙癢是自身免疫性和炎症性皮膚病的常見表現，非常不舒服，會對患者的生活質量產生負面影響。保濕劑、潤膚劑和屏障修復霜通常通過增強屏障功能來減少瘙癢。

新興市場的領先公司正在大力投資研發，以創造創新的瘙癢治療方法。還在進行投資以推進現有的治療方法。此外，推出新藥和建立強大的產品管線已成為領先企業的主要關注點。此外，非處方外用藥物由於成本低且易於獲得而需求量很大。因此，患者更頻繁地轉向非處方治療。這些因素為瘙癢產品的銷售增加和整體市場增長提供了有利的環境。然而，市場因缺乏對疾病原因的了解而受到阻礙。此外，各種瘙癢治療專利的到期為市場參與者提供了擴大業務的機會。

目錄

第 1 章 簡介

第二章執行摘要

第三章市場概況

  • 市場定義和範圍
  • 主要發現
    • 主要投資口袋
  • 波特五力分析
  • 大公司定位
  • 市場動態
    • 促進者
    • 抑製劑
    • 機會
  • COVID-19 影響分析

4. 瘙癢症治療市場，按藥物類型

  • 概述
    • 市場規模和預測
  • 皮質類固醇
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 抗組胺藥
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 局部麻醉劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 免疫抑製劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類

5. 瘙癢症治療市場，按疾病類型

  • 概述
    • 市場規模和預測
  • 特應性皮炎
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 過敏性接觸性皮炎
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 麻疹
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類

6. 瘙癢治療市場，按分銷渠道

  • 概述
    • 市場規模/預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 藥店和零售藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
    • 藥店和藥店的瘙癢治療藥物市場：按給藥途徑
      • 口服藥物市場規模和預測：按地區
      • 腸外藥物市場規模趨勢和預測：按地區
      • 外用藥物市場規模和預測：按地區
  • 在線提供商
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類

第七章瘙癢治療市場：按地區

  • 概述
    • 市場規模/預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按藥物類型
    • 北美市場規模和預測：按疾病類型
    • 北美市場規模和預測：按分銷渠道
      • 北美藥店和零售藥房市場的瘙癢症治療（按管理途徑）
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模和預測：按藥物類型
    • 歐洲市場規模和預測：按疾病類型
    • 歐洲市場規模和預測：按分銷渠道
      • 歐洲藥店和零售藥店治療瘙癢症的管理途徑市場
    • 歐洲市場規模和預測：按國家分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 歐洲其他地區
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太市場規模和藥物類型預測
    • 亞太地區市場規模和疾病類型預測
    • 亞太地區市場規模和分銷渠道預測
      • 瘙癢症市場的亞太藥店和零售藥房治療：按管理途徑
    • 亞太市場規模和預測：按國家分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 亞太其他地區
  • 拉美亞
    • 主要趨勢和機遇
    • 按藥物類型劃分的 LAMEA 市場規模和預測
    • 按疾病類型劃分的 LAMEA 市場規模和預測
    • LAMEA 市場規模和預測：按分銷渠道
      • LAMEA 藥店和零售瘙癢症藥物市場：按管理途徑
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其餘的 LAMEA

第八章 公司情況

  • 介紹
  • 關鍵成功策略
  • 10大公司產品圖
  • 比賽儀表板
  • 競爭熱圖
  • 重大發展

第九章公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • Cara therapeutics, Inc.
  • Cipla Ltd.
  • Eilly Lilly and company
  • Evelo Biosciences
  • Galderma S.A.
  • LEO Pharma
  • MC2 therapeuitics
  • Novan, Inc
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc
  • Sanofi
  • Trevi therapeutics
  • Viatris Inc.（Mylan NV）
Product Code: A17521

The global pruritus therapeutics market was valued at $7,849.4 million in 2021, and is projected to reach $11,186.15 million by 2031, registering a CAGR of 3.6% from 2022 to 2031. 

Pruritus therapeutics are medications used in treatment of pruritus. Pruritus causes itching of skin, owing to number of issues such as dry skin, allergy, and other ailments. It is a skin ailment that, if ignored, can cause persistent pain and have a negative influence on quality of life. For instance, anxiety, attention-deficit, or hyperactivity disorder and sleep disturbance can all be brought on by pruritus. In addition, it might result in systemic and mental conditions, if left untreated. A more significant underlying cause is typically indicated when pruritus persists for a longer time. A heightened inflammatory response to a multitude of possible irritants, such as dust, environmental pollutants, animals, and certain food can cause eczema, also known as atopic dermatitis. Atopic dermatitis commonly manifests as rashes, scaly areas, and itching on face, arms, or legs. Allergic contact dermatitis happens when people come into touch with substances that might harm their skin, such as chemicals. Typical products that cause contact dermatitis include watches, soaps, garments, and jewelry produced with potentially irritating substances. 

Medical professionals have utilized corticosteroids as a topical dosage form for treating pruritus for many years. The first-line pharmacological therapy for pruritus and associated skin itch diseases such AD, allergic contact dermatitis, and lichen planus is corticosteroids. Pruritus, a common sign of autoimmune and inflammatory skin conditions, can be extremely uncomfortable and negatively affect a patient's quality of life. Moisturizers, emollients, and barrier repair creams usually lessen pruritus by enhancing barrier function. 

Leading market players are significantly investing in research and development to create innovative pruritus therapies. Investments are also being made to advance existing therapeutics. In addition, launching new medications and building a strong product pipeline is the major focus of key players. Moreover, owing to their low cost and convenience of availability, over-the-counter topical medicines are in high demand. As a result, patients are turning more frequently to over-the-counter treatments. These drivers provide a favorable environment for increasing sales of pruritus products and for growth of the overall market. However, lack of knowledge regarding cause of the disease creates hindrance to the market. Moreover, patent expiry of various pruritus therapeutic products provide a greater opportunity for market players to grow their business.

The pruritus therapeutics market is segmented on the basis of drug type, disease, distribution channel, and region. On the basis of drug type, the market is segmented into corticosteroids, antihistamines, local anesthetics, immunosuppressants, and others. On the basis of disease type, it is segmented into atopic dermatitis, allergic contact dermatitis, urticaria, and others. On the basis of distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores & retail pharmacies segment is further segmented on the basis of route of administration into oral route, parenteral route, and topical route. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Major companies profiled in this report include AbbVie Inc., Amgen Inc., Bausch Health Companies Inc., Cara therapeutics, Inc., Cipla Ltd., Eilly Lilly and Company, Evelo Bioscience, Galderma S.A., LEO Pharma, MC2 Therapeuitics, Novan Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Trevi therapeutics and Viatris Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pruritus therapeutics market analysis from 2021 to 2031 to identify the prevailing pruritus therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the pruritus therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global pruritus therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug type

  • Corticosteroids
  • Antihistamines
  • Local Anesthetics
  • Immunosuppressant
  • Others

By Disease Type

  • Atopic Dermatitis
  • Allergic Contact Dermatitis
  • Urticaria
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug stores Retail Pharmacies
    • Route of Administration
    • Oral
    • Parenteral
    • Topical
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
    • Germany
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • AbbVie Inc.
    • Amgen Inc.
    • Bausch Health Companies Inc.
    • Cara therapeutics, Inc.
    • Cipla Ltd.
    • Eilly Lilly and company
    • Evelo Biosciences
    • Galderma S.A.
    • LEO Pharma
    • MC2 therapeuitics
    • Novan, Inc
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc
    • Sanofi
    • Trevi therapeutics
    • Viatris Inc. (Mylan NV)

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Corticosteroids
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Antihistamines
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Local Anesthetics
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Immunosuppressant
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country
  • 4.6 Others
    • 4.6.1 Key market trends, growth factors and opportunities
    • 4.6.2 Market size and forecast, by region
    • 4.6.3 Market analysis by country

CHAPTER 5: PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Atopic Dermatitis
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Allergic Contact Dermatitis
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Urticaria
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Others
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country

CHAPTER 6: PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Drug stores & Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
    • 6.3.4 Drug stores & Retail Pharmacies Pruritus Therapeutics Market by Route of Administration
      • 6.3.4.1 Oral Market size and forecast, by region
      • 6.3.4.2 Parenteral Market size and forecast, by region
      • 6.3.4.3 Topical Market size and forecast, by region
  • 6.4 Online providers
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: PRURITUS THERAPEUTICS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Drug type
    • 7.2.3 North America Market size and forecast, by Disease Type
    • 7.2.4 North America Market size and forecast, by Distribution Channel
      • 7.2.4.1 North America Drug stores & Retail Pharmacies Pruritus Therapeutics Market by Route of Administration
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Drug type
      • 7.2.5.1.2 Market size and forecast, by Disease Type
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Drug type
      • 7.2.5.2.2 Market size and forecast, by Disease Type
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Drug type
      • 7.2.5.3.2 Market size and forecast, by Disease Type
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Drug type
    • 7.3.3 Europe Market size and forecast, by Disease Type
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
      • 7.3.4.1 Europe Drug stores & Retail Pharmacies Pruritus Therapeutics Market by Route of Administration
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Drug type
      • 7.3.5.1.2 Market size and forecast, by Disease Type
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Drug type
      • 7.3.5.2.2 Market size and forecast, by Disease Type
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Drug type
      • 7.3.5.3.2 Market size and forecast, by Disease Type
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Drug type
      • 7.3.5.4.2 Market size and forecast, by Disease Type
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Drug type
      • 7.3.5.5.2 Market size and forecast, by Disease Type
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Drug type
      • 7.3.5.6.2 Market size and forecast, by Disease Type
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Drug type
    • 7.4.3 Asia-Pacific Market size and forecast, by Disease Type
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
      • 7.4.4.1 Asia-Pacific Drug stores & Retail Pharmacies Pruritus Therapeutics Market by Route of Administration
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Drug type
      • 7.4.5.1.2 Market size and forecast, by Disease Type
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Drug type
      • 7.4.5.2.2 Market size and forecast, by Disease Type
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Drug type
      • 7.4.5.3.2 Market size and forecast, by Disease Type
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Drug type
      • 7.4.5.4.2 Market size and forecast, by Disease Type
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Drug type
      • 7.4.5.5.2 Market size and forecast, by Disease Type
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Drug type
      • 7.4.5.6.2 Market size and forecast, by Disease Type
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Drug type
    • 7.5.3 LAMEA Market size and forecast, by Disease Type
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
      • 7.5.4.1 LAMEA Drug stores & Retail Pharmacies Pruritus Therapeutics Market by Route of Administration
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Drug type
      • 7.5.5.1.2 Market size and forecast, by Disease Type
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Drug type
      • 7.5.5.2.2 Market size and forecast, by Disease Type
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Drug type
      • 7.5.5.3.2 Market size and forecast, by Disease Type
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Drug type
      • 7.5.5.4.2 Market size and forecast, by Disease Type
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 AbbVie Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Amgen Inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Bausch Health Companies Inc.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Cara therapeutics, Inc.
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Cipla Ltd.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Eilly Lilly and company
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Evelo Biosciences
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Galderma S.A.
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 LEO Pharma
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 MC2 therapeuitics
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
  • 9.11 Novan, Inc
    • 9.11.1 Company overview
    • 9.11.2 Company snapshot
    • 9.11.3 Operating business segments
    • 9.11.4 Product portfolio
    • 9.11.5 Business performance
    • 9.11.6 Key strategic moves and developments
  • 9.12 Novartis AG
    • 9.12.1 Company overview
    • 9.12.2 Company snapshot
    • 9.12.3 Operating business segments
    • 9.12.4 Product portfolio
    • 9.12.5 Business performance
    • 9.12.6 Key strategic moves and developments
  • 9.13 Pfizer Inc.
    • 9.13.1 Company overview
    • 9.13.2 Company snapshot
    • 9.13.3 Operating business segments
    • 9.13.4 Product portfolio
    • 9.13.5 Business performance
    • 9.13.6 Key strategic moves and developments
  • 9.14 Regeneron Pharmaceuticals, Inc
    • 9.14.1 Company overview
    • 9.14.2 Company snapshot
    • 9.14.3 Operating business segments
    • 9.14.4 Product portfolio
    • 9.14.5 Business performance
    • 9.14.6 Key strategic moves and developments
  • 9.15 Sanofi
    • 9.15.1 Company overview
    • 9.15.2 Company snapshot
    • 9.15.3 Operating business segments
    • 9.15.4 Product portfolio
    • 9.15.5 Business performance
    • 9.15.6 Key strategic moves and developments
  • 9.16 Trevi therapeutics
    • 9.16.1 Company overview
    • 9.16.2 Company snapshot
    • 9.16.3 Operating business segments
    • 9.16.4 Product portfolio
    • 9.16.5 Business performance
    • 9.16.6 Key strategic moves and developments
  • 9.17 Viatris Inc. (Mylan NV)
    • 9.17.1 Company overview
    • 9.17.2 Company snapshot
    • 9.17.3 Operating business segments
    • 9.17.4 Product portfolio
    • 9.17.5 Business performance
    • 9.17.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 2. PRURITUS THERAPEUTICS MARKET SIZE, FOR CORTICOSTEROIDS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. PRURITUS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. PRURITUS THERAPEUTICS MARKET SIZE, FOR ANTIHISTAMINES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. PRURITUS THERAPEUTICS MARKET FOR ANTIHISTAMINES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. PRURITUS THERAPEUTICS MARKET SIZE, FOR LOCAL ANESTHETICS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. PRURITUS THERAPEUTICS MARKET FOR LOCAL ANESTHETICS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. PRURITUS THERAPEUTICS MARKET SIZE, FOR IMMUNOSUPPRESSANT, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. PRURITUS THERAPEUTICS MARKET FOR IMMUNOSUPPRESSANT, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 10. PRURITUS THERAPEUTICS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. PRURITUS THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 12. GLOBAL PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 13. PRURITUS THERAPEUTICS MARKET SIZE, FOR ATOPIC DERMATITIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. PRURITUS THERAPEUTICS MARKET FOR ATOPIC DERMATITIS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. PRURITUS THERAPEUTICS MARKET SIZE, FOR ALLERGIC CONTACT DERMATITIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. PRURITUS THERAPEUTICS MARKET FOR ALLERGIC CONTACT DERMATITIS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. PRURITUS THERAPEUTICS MARKET SIZE, FOR URTICARIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. PRURITUS THERAPEUTICS MARKET FOR URTICARIA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. PRURITUS THERAPEUTICS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. PRURITUS THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. GLOBAL PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 22. PRURITUS THERAPEUTICS MARKET SIZE, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. PRURITUS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 24. PRURITUS THERAPEUTICS MARKET SIZE, FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. PRURITUS THERAPEUTICS MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. GLOBAL DRUG STORES & RETAIL PHARMACIES PRURITUS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 27. PRURITUS THERAPEUTICS MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 28. PRURITUS THERAPEUTICS MARKET, FOR PARENTERAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 29. PRURITUS THERAPEUTICS MARKET, FOR TOPICAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 30. PRURITUS THERAPEUTICS MARKET SIZE, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 31. PRURITUS THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 32. PRURITUS THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 33. NORTH AMERICA PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 34. NORTH AMERICA PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 35. NORTH AMERICA PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 36. NORTH AMERICA DRUG STORES & RETAIL PHARMACIES PRURITUS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 37. NORTH AMERICA PRURITUS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 38. U.S. PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 39. U.S. PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 40. U.S. PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 41. CANADA PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 42. CANADA PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 43. CANADA PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 44. MEXICO PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 45. MEXICO PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 46. MEXICO PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 47. EUROPE PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 48. EUROPE PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 49. EUROPE PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 50. EUROPE DRUG STORES & RETAIL PHARMACIES PRURITUS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 51. EUROPE PRURITUS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 52. GERMANY PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 53. GERMANY PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 54. GERMANY PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 55. FRANCE PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 56. FRANCE PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 57. FRANCE PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 58. UK PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 59. UK PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 60. UK PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 61. ITALY PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 62. ITALY PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 63. ITALY PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 64. SPAIN PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 65. SPAIN PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 66. SPAIN PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 67. REST OF EUROPE PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 68. REST OF EUROPE PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 69. REST OF EUROPE PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 70. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 71. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 72. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 73. ASIA-PACIFIC DRUG STORES & RETAIL PHARMACIES PRURITUS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 74. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 75. JAPAN PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 76. JAPAN PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 77. JAPAN PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 78. CHINA PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 79. CHINA PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 80. CHINA PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 81. AUSTRALIA PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 82. AUSTRALIA PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 83. AUSTRALIA PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 84. INDIA PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 85. INDIA PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 86. INDIA PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 87. SOUTH KOREA PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 88. SOUTH KOREA PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 89. SOUTH KOREA PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 90. REST OF ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 92. REST OF ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 93. LAMEA PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 94. LAMEA PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 95. LAMEA PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 96. LAMEA DRUG STORES & RETAIL PHARMACIES PRURITUS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 97. LAMEA PRURITUS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 98. BRAZIL PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 99. BRAZIL PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 100. BRAZIL PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 101. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 102. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 103. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 104. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 105. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 106. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 107. REST OF LAMEA PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 108. REST OF LAMEA PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 109. REST OF LAMEA PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 110.ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 111.ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 112.ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 113.ABBVIE INC.: NET SALES,
  • TABLE 114.ABBVIE INC.: KEY STRATERGIES
  • TABLE 115.AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 116.AMGEN INC.: OPERATING SEGMENTS
  • TABLE 117.AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 118.AMGEN INC.: NET SALES,
  • TABLE 119.AMGEN INC.: KEY STRATERGIES
  • TABLE 120.BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
  • TABLE 121.BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
  • TABLE 122.BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
  • TABLE 123.BAUSCH HEALTH COMPANIES INC.: NET SALES,
  • TABLE 124.BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
  • TABLE 125.CARA THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 126.CARA THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 127.CARA THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 128.CARA THERAPEUTICS, INC.: NET SALES,
  • TABLE 129.CARA THERAPEUTICS, INC.: KEY STRATERGIES
  • TABLE 130.CIPLA LTD.: COMPANY SNAPSHOT
  • TABLE 131.CIPLA LTD.: OPERATING SEGMENTS
  • TABLE 132.CIPLA LTD.: PRODUCT PORTFOLIO
  • TABLE 133.CIPLA LTD.: NET SALES,
  • TABLE 134.CIPLA LTD.: KEY STRATERGIES
  • TABLE 135.EILLY LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 136.EILLY LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 137.EILLY LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 138.EILLY LILLY AND COMPANY: NET SALES,
  • TABLE 139.EILLY LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 140.EVELO BIOSCIENCES: COMPANY SNAPSHOT
  • TABLE 141.EVELO BIOSCIENCES: OPERATING SEGMENTS
  • TABLE 142.EVELO BIOSCIENCES: PRODUCT PORTFOLIO
  • TABLE 143.EVELO BIOSCIENCES: NET SALES,
  • TABLE 144.EVELO BIOSCIENCES: KEY STRATERGIES
  • TABLE 145.GALDERMA S.A.: COMPANY SNAPSHOT
  • TABLE 146.GALDERMA S.A.: OPERATING SEGMENTS
  • TABLE 147.GALDERMA S.A.: PRODUCT PORTFOLIO
  • TABLE 148.GALDERMA S.A.: NET SALES,
  • TABLE 149.GALDERMA S.A.: KEY STRATERGIES
  • TABLE 150.LEO PHARMA: COMPANY SNAPSHOT
  • TABLE 151.LEO PHARMA: OPERATING SEGMENTS
  • TABLE 152.LEO PHARMA: PRODUCT PORTFOLIO
  • TABLE 153.LEO PHARMA: NET SALES,
  • TABLE 154.LEO PHARMA: KEY STRATERGIES
  • TABLE 155.MC2 THERAPEUITICS: COMPANY SNAPSHOT
  • TABLE 156.MC2 THERAPEUITICS: OPERATING SEGMENTS
  • TABLE 157.MC2 THERAPEUITICS: PRODUCT PORTFOLIO
  • TABLE 158.MC2 THERAPEUITICS: NET SALES,
  • TABLE 159.MC2 THERAPEUITICS: KEY STRATERGIES
  • TABLE 160.NOVAN, INC: COMPANY SNAPSHOT
  • TABLE 161.NOVAN, INC: OPERATING SEGMENTS
  • TABLE 162.NOVAN, INC: PRODUCT PORTFOLIO
  • TABLE 163.NOVAN, INC: NET SALES,
  • TABLE 164.NOVAN, INC: KEY STRATERGIES
  • TABLE 165.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 166.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 167.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 168.NOVARTIS AG: NET SALES,
  • TABLE 169.NOVARTIS AG: KEY STRATERGIES
  • TABLE 170.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 171.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 172.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 173.PFIZER INC.: NET SALES,
  • TABLE 174.PFIZER INC.: KEY STRATERGIES
  • TABLE 175.REGENERON PHARMACEUTICALS, INC: COMPANY SNAPSHOT
  • TABLE 176.REGENERON PHARMACEUTICALS, INC: OPERATING SEGMENTS
  • TABLE 177.REGENERON PHARMACEUTICALS, INC: PRODUCT PORTFOLIO
  • TABLE 178.REGENERON PHARMACEUTICALS, INC: NET SALES,
  • TABLE 179.REGENERON PHARMACEUTICALS, INC: KEY STRATERGIES
  • TABLE 180.SANOFI: COMPANY SNAPSHOT
  • TABLE 181.SANOFI: OPERATING SEGMENTS
  • TABLE 182.SANOFI: PRODUCT PORTFOLIO
  • TABLE 183.SANOFI: NET SALES,
  • TABLE 184.SANOFI: KEY STRATERGIES
  • TABLE 185.TREVI THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 186.TREVI THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 187.TREVI THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 188.TREVI THERAPEUTICS: NET SALES,
  • TABLE 189.TREVI THERAPEUTICS: KEY STRATERGIES
  • TABLE 190.VIATRIS INC. (MYLAN NV): COMPANY SNAPSHOT
  • TABLE 191.VIATRIS INC. (MYLAN NV): OPERATING SEGMENTS
  • TABLE 192.VIATRIS INC. (MYLAN NV): PRODUCT PORTFOLIO
  • TABLE 193.VIATRIS INC. (MYLAN NV): NET SALES,
  • TABLE 194.VIATRIS INC. (MYLAN NV): KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.PRURITUS THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 2.PRURITUS THERAPEUTICS MARKET,2021-2031
  • FIGURE 3.PRURITUS THERAPEUTICS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.PRURITUS THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.PRURITUS THERAPEUTICS MARKET,BY DRUG TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDS PRURITUS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANTIHISTAMINES PRURITUS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF LOCAL ANESTHETICS PRURITUS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF IMMUNOSUPPRESSANT PRURITUS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS PRURITUS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 18.PRURITUS THERAPEUTICS MARKET,BY DISEASE TYPE,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ATOPIC DERMATITIS PRURITUS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF ALLERGIC CONTACT DERMATITIS PRURITUS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF URTICARIA PRURITUS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF OTHERS PRURITUS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 23.PRURITUS THERAPEUTICS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES PRURITUS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF DRUG STORES & RETAIL PHARMACIES PRURITUS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS PRURITUS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 27.PRURITUS THERAPEUTICS MARKET BY REGION,2021
  • FIGURE 28.U.S. PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 29.CANADA PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 30.MEXICO PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 31.GERMANY PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 32.FRANCE PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 33.UK PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 34.ITALY PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 35.SPAIN PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 36.REST OF EUROPE PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 37.JAPAN PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 38.CHINA PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 39.AUSTRALIA PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 40.INDIA PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 41.SOUTH KOREA PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 42.REST OF ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 43.BRAZIL PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 44.SAUDI ARABIA PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 45.SOUTH AFRICA PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 46.REST OF LAMEA PRURITUS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 50.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 51.COMPETITIVE DASHBOARD
  • FIGURE 52.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 53.ABBVIE INC..: NET SALES ,($MILLION)
  • FIGURE 54.AMGEN INC..: NET SALES ,($MILLION)
  • FIGURE 55.BAUSCH HEALTH COMPANIES INC..: NET SALES ,($MILLION)
  • FIGURE 56.CARA THERAPEUTICS, INC..: NET SALES ,($MILLION)
  • FIGURE 57.CIPLA LTD..: NET SALES ,($MILLION)
  • FIGURE 58.EILLY LILLY AND COMPANY.: NET SALES ,($MILLION)
  • FIGURE 59.EVELO BIOSCIENCES.: NET SALES ,($MILLION)
  • FIGURE 60.GALDERMA S.A..: NET SALES ,($MILLION)
  • FIGURE 61.LEO PHARMA.: NET SALES ,($MILLION)
  • FIGURE 62.MC2 THERAPEUITICS.: NET SALES ,($MILLION)
  • FIGURE 63.NOVAN, INC.: NET SALES ,($MILLION)
  • FIGURE 64.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 65.PFIZER INC..: NET SALES ,($MILLION)
  • FIGURE 66.REGENERON PHARMACEUTICALS, INC.: NET SALES ,($MILLION)
  • FIGURE 67.SANOFI.: NET SALES ,($MILLION)
  • FIGURE 68.TREVI THERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 69.VIATRIS INC. (MYLAN NV).: NET SALES ,($MILLION)